Objective: To investigate the mechanisms underlying the antiobesity effects of a novel isoflavone-free peptide mixture (BSP) derived from black soybean. Design: Long-term effects of BSP were evaluated in diet-induced obese (DIO) mice fed a high-fat (HF) diet without or with BSP (2, 5 or 10% of energy) for 13 weeks, or for 8 weeks in combination with exercise. Acute effects of BSP on food intake and body weight in rats and leptin-deficient ob/ob mice were evaluated. Cell culture models or tissue extracts were used to investigate the mechanisms underlying the antiobesity effect. Measurement: Total food intake, body weight gain, white adipose tissue (WAT) mass, plasma concentrations of leptin, adiponectin, cholesterol and triglyceride were measured. Janus kinase 2 (JAK2)-dependent signal transducers and activators of the transcription 3 (STAT3) phosphorylation and AMP-activated protein kinase (AMPK) activity were determined using Westernblot in cultured cells or tissue extracts. Results: DIO mice fed an HF diet with BSP (2, 5 or 10%) for 13 weeks gained less body weight (21.4, 19.8 or 17.1 g, respectively) than the mice fed an HF diet without BSP (22.6 g) concurrent with inhibition of total food intake in a dosedependent manner. BSP also significantly decreased food intake in rats and leptin-deficient ob/ob mice. The highest dose of BSP (10%) significantly elevated the plasma adiponectin and decreased plasma triglyceride. BSP activated JAK2-dependent STAT3 in a cell model, and elevated the level of hypothalamic phospho-STAT3 in ob/ob mice. BSP also phosphorylated AMPK and acetylCoA carboxylase of C2C12 myocytes in a dose-dependent manner. The antiobesity effect was augmented by low-intensity wheel-based exercise. In exercised mice, BSP significantly decreased periepididymal WAT mass and body weight gain. Conclusion: These results provided evidences that BSP decreased appetite and HF diet-induced body weight gain particularly in combination with exercise, through leptin-like STAT3 phosphorylation and AMPK activation.
Introduction
Obesity is a major contributor to the burden of chronic disease and disability in developed countries. Despite public health education, the prevalence of obesity continues to increase and 430% of adults in the United States are obese. 1, 2 Clinicians have few tools to address the obesity epidemic. Although a number of chemically derived agents, to treat obesity, have been developed recently or are in clinical trials, there are only a few successful agents for longterm treatment of obesity, such as orlistat and sibutramine. 3 The use of most agents developed to date is limited by unacceptable adverse reactions or the potential for abuse during long-term pharmacotherapy. 4 Therefore, new therapeutics to reduce body weight with minimal adverse reactions will be beneficial.
Nutritional intervention studies performed in animals and humans show that dietary soybean has beneficial health effects. [5] [6] [7] [8] [9] [10] For example, several studies have shown that the isoflavones and high-quality protein, the major components of a soy diet, may be responsible for the beneficial effects against a variety of disorders including obesity, diabetes, cardiovascular disease, hyperlipidemia and various forms of chronic renal disease. Because of the unknown complex interactions between soy protein and isoflavones in a soy diet, it is difficult to evaluate the biological activity of each component without isolating and studying each compound. 11 However, soy protein isolates, generally used in most studies, contain a significant amount of isoflavones including genistein, daidzein and glycitein. 12, 13 Although several studies have shown that the isoflavones are the major contributor to the beneficial effects of soy protein isolates including their hypocholesterolemic, antiadiposity and antiobesity effects, 6, [14] [15] [16] other studies have shown that soy protein with negligible amounts of isoflavone also have biological effects on metabolic disorders. 15, 17 It is controversial whether soy protein itself has a protective effect against obesity and related diseases. [18] [19] [20] Recent studies show that, in addition to the soy protein and isoflavones, peptides or protein molecules derived from soy protein isolates have biological activity against obesity by modulating endogenous anorexic factors. 7, 8, 20, 21 Anorexic and thermoregulation signaling most definitely play a major role in regulating body weight. Although whole-body energy homeostasis is maintained by multiple pathways, most antiobesity drugs target one. Among the multiple pathways, there are attractive pathways involved both in food intake and thermoregulation including leptinmediated signaling and AMP-activated protein kinase (AMPK) pathways. In connection with these, recent studies show that leptin and the AMPK pathway are the most important therapeutic targets for regulating appetite and whole-body energy balance. [22] [23] [24] Therefore, agent having the activity of these pathways can be the more promising antiobesity agents.
We have recently established a method for extracting an isoflavone-free novel peptide mixture (BSP) derived from the protein of black soybean (Rhynchosia volubilis). We reported that the BSP peptide mixture decreases body weight and has a hypocholesterolemic effect in diet-induced obese (DIO) rats. 25 We did not investigate the mechanisms underlying these antiobesity effects or the long-term effects of BSP in the previous study. Against these backgrounds, the purpose of this study was to confirm the antiobesity effects of BSP using a DIO model in obesity-prone C57/Bl6 mice fed a high-fat (HF) diet for 13 weeks and to investigate the mechanisms underlying the antiobesity effects of BSP in vivo (using ob/ob mice or rats) and in vitro (using SH-SY5Y or C2C12 cells). In addition, we evaluated the effects of exercise with light intensity on the BSP-mediated inhibition of the HF dietinduced obesity in mice for 8 weeks. Nonexercise experiment. To study the effects of BSP on the development of HF diet-induced obesity, C57Bl/6 mice (n ¼ 44) were fed HF diet with or without BSP, or low-fat (LF) diet for 13 weeks. After 1 week of acclimation, mice were fed the HF diet alone (HFD group) comprising a modified AIN-76A diet with 40% beef tallow (Dyets Inc., Bethlehem, PA, USA), or HF diet with BSP contained (w/w) 2, 5 or 10% BSP (2, 5 or 10% group, respectively, n ¼ 9 per group). All obesity-prone diets were isocaloric. This obesity-prone diets contained beef tallow (65.2% energy as fat), casein (or casein þ BSP, 13.2% energy as protein), sucrose and starch (20.6% energy as carbohydrate), vitamin and mineral mix (1.2% energy) and cellulose. Lean control mice (LFD group) were fed with a matched LF diet (AIN-76A; n ¼ 8) without BSP. Body weight and amount of food intake of each animal were measured every 6 days and daily (between 1600 and 1800 hours), respectively. Epididymal white adipose tissue (WAT) mass and plasma biochemical parameters were measured at the end of the experimental period.
Materials and methods

Materials
Exercise experiment. In cell culture experiments, we observed that BSP activated AMPK and its downstream target protein (ACC) of myotubes in the present study (see Results). It is well known that exercise is a physiologic stimulus activating AMPK. To study the combined effects of BSP and exercise, therefore, mice fed either the HF diet or the LF diet were adapted to the forced exercise wheel system (Lafayette Instrument Co., IN, USA) for 5 consecutive days by running at 4 m min À1 for 30 min and then 8 m min À1 for 30 min. After acclimation, mice were exposed to forced wheel-based exercise for 1 h every day, running at 8 m min À1 at 1700-1800 hours for 8 weeks, during which time they were given free access to the LF diet (eLFD group), HF diet (eHFD group) or one of three HF diet with 2, 5 or 10% BSP for 8 weeks (n ¼ 7 per group). Body weight, daily food intake and WAT mass were measured as method as stated in the methods of the nonexercise experiment.
Tissue preparation and measurement of blood parameters At the end of the nonexercised experimental period (13 weeks), after overnight fasting, blood was drawn by cardiac puncture under ketamine-xylazine-induced anesthesia at 1600-1800 hours. Plasma leptin and adiponectin concentrations were measured using commercially available immunoassay kits (R&D Systems, Minneapolis, MN, USA). The concentrations of total cholesterol and triglycerides in plasma were measured by commercial kits (Asan Co., Seoul, South Korea). Periepididymal WAT and soleus muscle of mice with (8 weeks experiment) or without exercise (13 weeks experiment) were quickly removed, weighed and immediately frozen in liquid nitrogen for subsequent immunoblotting. The brains of ob/ob mice were removed quickly and the medial basal hypothalamus was dissected out, frozen in liquid nitrogen and kept at À80 1C.
Experiments to investigate the effects of acute intervention
To evaluate the activating effect of BSP on JAK2-STAT3 signaling independent of endogenous leptin, we used leptindeficient ob/ob mice. Osmotic minipumps (flow rate: 0.25 ml h À1 ) containing vehicle (sterile saline) or BSP (125 mg h À1 ) were placed in the intraperitoneal cavity of 9-week-old leptin-deficient mice (ob/ob, n ¼ 4-5; Central Laboratory Animal Inc.) under ketamine-xylazine-induced anesthesia. The mice were then housed individually and given free access to a chow diet and water for 2 weeks. Two weeks after insertion of the osmotic pumps, total food intake (sum of daily food intake) and body weight gain (body weight was determined every 2 days) were measured.
Sprague-Dawley rats (n ¼ 6-8 per group) aged 8 weeks, were starved for 24 h and injected intraperitoneally with saline vehicle or BSP (100, 250 or 500 mg per kg) at 1700 hours. Poststarvation food intake on the chow diet was measured for the next 24 h.
Statistics
All data are presented as means±s.e.m. except when stated otherwise. The effects of the treatments were compared using the Mann-Whitney U-test or Kruskal-Wallis test Antiobesity mechanisms of black soy peptides E-H Jang et al followed by Dunn's comparisons using GraphPad Prism program version 3.0 (GraphPad Software, San Diego, CA, USA). The significances of differences in body weight gain between groups over the study period (2, 8 or 13 weeks) were analyzed by repeated measures analysis of variance (RM-ANOVA) followed by Tukey's multiple comparisons. We considered Po0.05 as significant.
Results
Effects of BSP on food intake and body weight gain in DIO mice To determine the impact of diet containing various doses of BSP in DIO mice, we measured body weight gain during the 13 weeks. As shown in Figure 1a , body weight gain throughout the study differed significantly between the groups fed the HF diet (P ¼ 0.0007). As expected, mice on the HF diet gained more weight (22.6 ± 1.16 g) than mice fed the LF diet (5.2±0.75 g). Mice fed the HF diet containing 5% BSP (19.9 ± 0.98 g, Po0.05) and 10% BSP (17.1 ± 2.55 g, Po0.01) gained significantly less weight than mice fed the HF diet alone (Figure 1b) . Mice fed the HF diet with 2% BSP gained less weight (21.4 ± 1.83 g) than the HFD group, although this trend was not significant. BSP decreased the total amount of food intake throughout the study period in a dose-dependent manner (Figure 1c) .
WAT mass and blood biochemistry in mice fed HF At the end of 13-week experiment, WAT mass, and the concentrations of plasma leptin, total cholesterol and triglyceride were higher, and serum adiponectin concentration was lower in HFD group than in LFD group ( Table 1) . The high dose (10%) of BSP significantly decreased serum triglyceride concentration (Po0.01 versus HFD) and increased serum adiponectin concentration (Po0.05 versus HFD). The mean weight of epididymal WAT and plasma leptin concentration tended to be lower with increasing BSP content, but this trend was not significant. To exclude the involvement of hepatotoxicity in BSP-induced body weight reduction, plasma levels of liver enzymes were measured. The plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was increased by HFD without statistical significance, and which was not significantly elevated further by BSP-containing diet with large interindividual variability (Table 1) .
Effects of BSP in acute intervention
Leptin is a major satiety factor acting on the hypothalamic appetite center through activation of JAK2-STAT3 phosphorylation. Because chronic feeding of BSP inhibits total food intake, we examined the effects of BSP on hypothalamic STAT3 activation in leptin-deficient ob/ob mice. Body weight gain was inhibited significantly in mice with intraperitoneal pumps that released BSP constantly for 2 weeks (Figure 2a) . Figure 2b indicates that appetite was suppressed in mice infused with BSP during the 2 weeks. Four days after the insertion of the pumps, the mice recovered body weight and then gained body weight throughout the 2 weeks. However, the pattern of body weight gain (Figure 2c ; P ¼ 0.0055) or mean body weight gain (Figure 2a ; Po0.05) was significantly different between the BSP group and the vehicle control group. STAT3 phosphorylation was greater in the hypothalamus of ob/ob mice treated with BSP than in the vehicle control mice (Figure 2c) . A dose-dependent appetitesuppressing effect of BSP was also observed in rats treated with a single intraperitoneal injection of BSP (Figure 2d ).
Effects of BSP on the JAK2/STAT3-dependent leptin-signaling pathway in a cellular model To evaluate the mechanism of the in vivo leptin-like anorexic effect, we tested the effect of BSP on the major signaling 
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Combined effects of BSP and low-intensity exercise Regular exercise training and physical activity increase the oxidation of fat and this effect is important in preventing lifestyle diseases such as obesity. Some investigators have suggested that dietary soy protein intake and exercise have an additive effect in stimulating fatty-acid oxidation and regulating body weight. 28, 29 Although there is a limitation to direct comparison, exercised mice fed the HF diet (eHFD group) gained less body weight (9.12±1.56 g) over the 8 weeks than the nonexercised mice fed the HF diet (HFD group at 8 weeks in nonexercise experiment during 13 weeks; 16 ± 2.56 g). Body weight gain differed significantly between exercised mice fed the HF diet with and without BSP (Figure 4a ; P ¼ 0.0028). As shown in Figure 4b , total body weight gain was significantly lower in exercised mice fed the HF diet with 5% BSP (5.60±1.28 g) or 10% BSP (5.46±1.60 g) than the eHFD group (Po0.01). The patterns of decreased food intake and body weight gain were similar to those in the results of the experiment without exercise. BSP and exercise seemed to have an additive effect on fat reduction. The mean WAT mass was significantly lower in exercised mice fed the HF diet with 5 or 10% BSP than the mice fed the HF diet without BSP (eHFD; Figure 4d ).
Effects of BSP on AMPK phsophorylation in C2C12 myocytes
AMPK stimulates fatty-acid oxidation and decreases blood glucose concentration through leptin-dependent or leptinindependent pathways, and the exercise directly activates AMPK. 30, 31 Our in vivo evidences reported here showed that BSP has leptin-like anorectic property and fat-lowering effects in combination with exercise. Dietary BSP (10%) partially but significantly restores the HF diet-induced decrease in plasma adiponectin concentration that is an important intrinsic stimulator of AMPK. 30, 32 To study this further, we evaluated the effect of BSP on AMPK activation in C2C12 myocytes. As shown in Figure 5 , the treatment of myocytes with various concentrations of BSP directly activated AMPK phosphorylation and its subsequent downstream pathway, ACC. Triplicate experiments showed that treatment of myocytes with concentrations as low as 1 mg ml À1 of BSP activated AMPK.
Tissue dependent effects of BSP on AMPK
To determine the effect of BSP (10%) on the AMPK activation, we measured the expression level of AMPK and phosphorylated AMPK (pAMPK) in WAT and skeletal muscles collected after 13 weeks dietary intervention. The effects of BSP on the expression of pAMPK were tissue specific in vivo.
As shown in Figure 6 , the expression of pAMPK in skeletal muscle did not change, even in response to the highest dose of BSP (10%). However, although there was interindividual variation in the responses, the expression of pAMPK in WAT significantly decreased after the HF diet without BSP, and the expression level was significantly restored by the addition of 10% BSP (Po0.05 versus HFD group, n ¼ 8).
Discussion
We reported previously on the weight-reducing and hypocholesterolemic effects of BSP in the DIO rat for 4 weeks, but we did not investigate the mechanisms responsible for these Antiobesity mechanisms of black soy peptides E-H Jang et al effects. 25 The purpose of our present study was to confirm the long-term antiobesity effect of BSP and to investigate the mechanisms underlying its dietary and hypocholesterolemic effects using in vivo and in vitro experiments. A novel peptide mixture, BSP does not contain a significant amount of isoflavone, and small-sized peptides (o10 kDa) comprise 480% of BSP. 25, 33 Although there are some differences in species (rat or mice), diets (high fat and cholesterol, or high fat) and duration of intervention (4 or 13 week) between our previous studies and the current study, we confirmed the antiobesity and hypotriglyceridemic effect of BSP in a longer intervention study. To further elicit the underlying molecular mechanisms for the primary results of body weight lowering and of appetite suppressing effects in animals, we focused on two major signaling pathways for body weight regulation, JAK2-STAT3 and AMPK-ACC phosphorylation. Firstly, we were concerned about an anorexic signaling pathway activated by an important circulating satiety factor, leptin. The leptin-mediated STAT3 phosphorylation pathway in the hypothalamus is a major cellular mechanism among the multiple pathways involved in suppressing food intake and promoting energy expenditure. 34, 35 In both the acute (for 2 weeks in ob/ob mice) and chronic (for 13 weeks) intervention models, BSP significantly decreased total food intake and body weight gain (Figures 1 and 2 ). The inhibition of HFD-induced hypertrigylceridemia by BSPcontaining diet (Table 1) for 13 weeks is consistent with our previous study. 25 Pharmacologic features of BSP is induction of hypothalamic STAT3 phosphorylation in leptin-deficient ob/ob mice concurrently with the decreased food intake and body weight gain, suggesting that the activation of leptin-like signaling is involved in the anorectic effect of BSP. Involvement of hepatocyte damage in the body weight lowering effect of BSP is unlikely, because plasma ALT and AST levels were not elevated further by dietary BSP (Table 1) . We also confirmed the leptin receptor-and JAK2-dependent activation by BSP of STAT3 signaling in LEPRexpressing neuronal cells; this occurred at a concentration as low as 1 mg ml
À1
, indicating that the inhibition of food intake by BSP in chronic dietary intervention involves activation of leptin-like signaling in the hypothalamus. We could not fully evaluate the pharmacokinetic features of BSP, including the distribution of peptides into the brain, because BSP comprises many peptides. However, we could detect a Antiobesity mechanisms of black soy peptides E-H Jang et al specific hepta-peptide (IPPGVPY; BSP contains this peptide at concentration of 50 mg per g) in plasma at 30 min after oral administration of BSP (1 g) in rats (Supplementary Information), suggesting that peptides in the BSP mixture might be absorbed through gastrointestinal tract as intact molecules. We plan to identify the peptide(s) responsible for the activation of STAT3 or AMPK, and if successful, we will investigate the pharmacokinetic profiles of the peptide(s). Another important pathway for body weight regulation is AMPK activation followed by ACC inhibition. AMPK functions as a sensor of the intracellular energy state and is activated by exercise, adiponectin, leptin and sympathetic outflow. 31 In the long-term dietary intervention study, plasma concentration of adiponectin increased significantly after mice were fed the high dose of BSP (10%). Adiponectin has received a great deal of attention because it decreases the concentrations of plasma triglycerides and free fatty acids primarily through the activation of AMPK. 30, 32, 36 In skeletal muscle cells, activated AMPK increases fatty-acid oxidation through the influx of long-chain fatty acids into the mitochondria. In our cellular model, BSP directly activated the phosphorylation of AMPK and the subsequent inhibition (phosphorylation) of ACC, suggesting that the hypotriglyceridemic effect of BSP is related to the activation of AMPK. Interestingly, 13 weeks of dietary BSP increased the level of pAMPK in a tissue-specific manner, suggesting that other pathway(s) are involved in the beneficial effects of BSP. Expression of pAMPK in skeletal muscle did not differ between the mice fed the HF diet with or without BSP. This raises the question whether the difference between our in vivo and in vitro results can be explained by the distribution profile of BSP in vitro. BSP comprises diverse peptides, and the pharmacokinetic profiles of these unknown peptides may differ. Therefore, different tissue distribution of the peptide may play a role in AMPK activation. This possibility is supported indirectly by the Antiobesity mechanisms of black soy peptides E-H Jang et al exercise experiment, which showed an additive effect of the BSP-containing diet combined with low-intensity exercise (8 m min À1 for 1 h, every day) in decreasing body fat. AMPK in skeletal muscle is activated by exercise. Therefore, the BSPinduced activation of AMPK in WAT, and exercise-induced activation of AMPK in skeletal muscle, may act additively to enhance fat reduction. Further studies are warranted to confirm this conclusion. A recent study showed consistency with our results that dietary soy protein intake and exercise training have an additive effect on the activation of enzymes related to fatty-acid oxidation in rats, although this study did not report the composition of the soy protein, particularly isoflavones. 29 Currently available soybean proteins and foods contain significant amounts of isoflavones such as daidzein and genistein. These isoflavones have estrogenic (phytoestrogens) effects. Also, the hypocholesterolemic effect of isoflavones may play a role in beneficial effects of soy proteins and foods. [37] [38] [39] [40] Studies using diets made from soy isolates, with or without isoflavones, show that isoflavones probably contribute to the hypocholesterolemic effect. 14, 15 A number of studies have reported the beneficial health effects of soy proteins and foods, although the potential health effects of isoflavone-rich soy diets have not been confirmed as resulting from the hormonal effects. 41, 42 BSP is a peptides mixture that does not contain a significant amount of isoflavone, supporting the notion that the in vivo and in vitro biological effects are caused by peptides itself and not by isoflavones. Indeed, we could not find a significant amount of two major isoflavones glycosides, daidzin (not detected) and genistin (8.6 mg per g BSP) and their aglycones, daidzein (4.6 mg per g BSP) and genistein (3.5 mg per g BSP).
BSP contains various sizes of peptides as described above, and we cannot exclude the possibility that the biological functions that we observed relate to more than one peptide. Further study is needed to reveal the functions of individual peptides comprising BSP.
In conclusion, we confirmed the antiobesity and hypotriglyceridemic effects of BSP, a novel peptide mixture, in mice fed an HF diet for 13 weeks. These beneficial effects of BSP were related to JAK2-dependent STAT3 activation and to direct AMPK activation. In addition, the antiobesity and fatdecreasing effects of BSP increased when combined with lowintensity exercise. These data suggest that BSP is a useful peptide to help regulate body weight gain and hypertriglyceridemia. Future studies are needed to document the pharmacokinetic profiles of BSP in animals and humans, and to identify the actions and clinical applications of individual peptides.
